LAUSR

Background: The advent of tyrosine kinase inhibitors (TKIs) has transformed the prognosis of CML. Prolonged survival has already been achieved in most patients with access to these drugs, and as access improves in more resource-constrained settings, it should be expected that this improvement will become more common, thus increasing the prevalence of CML. Aim: Through this analysis, we aim to understand the global impact of targeted therapy on CML prevalence over the next ten years. Methods: Using a critically appraised set of country-specific cancer registries, CML incidence was estimated for 45 countries, representing approximately 90% of the world population in 2018. An assumptions-based 10-year forecast model was used to incorporate the effects of improving access to TKIs in developing countries using an observed correlation between gross domestic product per capita, CML risk, and survival (Fig 1). To represent the continuing optimization of TKI-based treatments, survival was further trended based on ...